HSPG2 anticorps

N° du produit ABIN3023903

Détail du produit anti-HSPG2 anticorps

Antigène: HSPG2 (Heparan Sulfate Proteoglycan 2 (HSPG2))

Reactivité: Humain, Souris, Boeuf (Vache), Poisson, Singe, Porc

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp HSPG2 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Flow Cytometry (FACS)

Attributs du produit: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.

Purification: Protein G affinity chromatography

Immunogène: A murine EHS laminin preparation was used as the immunogen for the anti-Perlecan antibody.

Clone: SPM255

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal dilution of the anti-Perlecan antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2)

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store the anti-Perlecan antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur HSPG2

Antigène: HSPG2 (Heparan Sulfate Proteoglycan 2 (HSPG2))

Autre désignation: Perlecan (HSPG) (HSPG2 Produits)

Synonymes: anticorps HSPG, anticorps PLC, anticorps PRCAN, anticorps SJA, anticorps SJS, anticorps SJS1, anticorps HSPG2, anticorps AI852380, anticorps Pcn, anticorps Plc, anticorps per, anticorps Per, anticorps heparan sulfate proteoglycan 2, anticorps perlecan (heparan sulfate proteoglycan 2), anticorps HSPG2, anticorps hspg2, anticorps Hspg2

Sujet: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.

Pathways: Glycosaminoglycan Metabolic Process, Lipid Metabolism